CliffBio
small molecule

XADAGO

SAFINAMIDE MESYLATE

Loss of exclusivityMarch 2031latest FDA-listed patent expiry
CompanyMDD US OPERATIONS, LLC →See this company's full patent-cliff portfolio

Drug detail

Brand nameXADAGO
Active ingredientSAFINAMIDE MESYLATE
StrengthEQ 100MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2017
Marketing statusRX

Listed patents

PatentExpiresType
8283380March 2031use U-1993
8076515December 2028substance, product
8278485June 2027substance

More from MDD US OPERATIONS, LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XADAGO patent cliff — loss of exclusivity March 2031 | CliffBio